KRAS and bile duct cancer: In a previous study, we attempted to predict a primary site based on histopathology, IHC examinations, KRAS mutation, elevation of tumor markers (CA19-9 and CEA), and metastatic site distribution to distinguish gastric, pancreatic, and bile duct cancer profiles [7].